Serbia’s Hemofarm to invest 100 min euro in supply chain

Numerous projects that are in the pipeline over the next few years will positioning Hemofarm among mega-production hubs, even on an international scale, Hemofarm’s general director Ronald Zeliger said in a press release on Monday.

In 2023, Hemofarm anticipates double-digit growth, fueled by the introduction of new medications for multiple sclerosis and a novel flu virus treatment.

Stada, which took over Hemofarm in 2006, has so far invested more than 450 million euro in the modernisation of equipment and production facilities in Serbia's eastern town of Vrsac.

Hemofarm’s factories are located in Serbia, Montenegro and Bosnia and Herzegovina.

$ = 0.9242 euro